LYRA
Closed
Lyra Therapeutics inc
8.895
-0.065 (-0.73%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 8.96
Day's Range: 8.5019 - 9.28
Send
sign up or login to leave a comment!
When Written:
2.35
Lyra Therapeutics Inc is a clinical-stage biotechnology company that is focused on developing innovative therapies for the treatment of ear, nose, and throat (ENT) diseases. The company's proprietary technology platform, called XTreo, is designed to enable the sustained release of therapeutic agents directly to the affected tissue in the ENT region. This approach is intended to improve the efficacy and safety of existing treatments and to enable the development of new therapies for ENT diseases.
Lyra Therapeutics was founded in 2015 and is headquartered in Watertown, Massachusetts. The company's lead product candidate is LYR-210, which is being developed as a treatment for chronic rhinosinusitis (CRS), a common ENT disease that affects millions of people worldwide. LYR-210 is currently in Phase 2 clinical trials, and the company has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of CRS.
In addition to LYR-210, Lyra Therapeutics is also developing other product candidates using its XTreo platform, including treatments for otitis media (middle ear infection) and laryngopharyngeal reflux (LPR), a condition that can cause chronic cough and other symptoms. The company has partnerships with several academic institutions and research organizations to support its development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Lyra Therapeutics was founded in 2015 and is headquartered in Watertown, Massachusetts. The company's lead product candidate is LYR-210, which is being developed as a treatment for chronic rhinosinusitis (CRS), a common ENT disease that affects millions of people worldwide. LYR-210 is currently in Phase 2 clinical trials, and the company has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of CRS.
In addition to LYR-210, Lyra Therapeutics is also developing other product candidates using its XTreo platform, including treatments for otitis media (middle ear infection) and laryngopharyngeal reflux (LPR), a condition that can cause chronic cough and other symptoms. The company has partnerships with several academic institutions and research organizations to support its development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!